Each tablet contains Gliclazide 80 mg and Metformin Hydrochloride 500 mg.

Dianorm M Tablets combine Gliclazide, a second-generation sulfonylurea, with Metformin Hydrochloride, a biguanide antihyperglycemic agent, to provide dual-mechanism glycemic control in adults with type 2 diabetes mellitus. Gliclazide stimulates insulin secretion from functioning pancreatic β-cells, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity. The combination helps achieve effective blood glucose control in patients who are inadequately managed with diet, exercise, or single-drug therapy.

Dianorm M Tablets are indicated for the treatment of non-insulin-dependent diabetes mellitus (Type 2 diabetes mellitus) in adult patients whose blood glucose levels are not adequately controlled with diet, exercise, and monotherapy.

Gliclazide stimulates the release of insulin from pancreatic β-cells by facilitating calcium ion (Ca²⁺) transport across the β-cell membrane, thereby enhancing glucose-dependent insulin secretion. It also helps reduce the amount of glucose absorbed from food and decreases hepatic glucose production. Metformin Hydrochloride decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Together, these complementary mechanisms improve fasting and postprandial blood glucose control while reducing insulin resistance.

The recommended dosage is one tablet taken orally twice daily or as directed by the treating physician. The tablets should preferably be administered with meals to minimize gastrointestinal adverse effects. Dosage should be individualized according to the patient's glycemic response and clinical condition.

Dianorm M Tablets are contraindicated in patients with known hypersensitivity to Gliclazide, Metformin, or any component of the formulation. The medication is also contraindicated in patients with type 1 diabetes mellitus, diabetic pre-coma or coma, diabetic ketoacidosis, severe renal or hepatic insufficiency, patients receiving Miconazole therapy, during pregnancy and lactation, and in patients with porphyria where Gliclazide should be avoided whenever possible.